|
|
|
|
|
|
Sponsors and Collaborators: |
Case Comprehensive Cancer Center National Cancer Institute (NCI) |
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00608205 |
RATIONALE: Radiation therapy uses high energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving radiation therapy together with cisplatin and fluorouracil may kill more tumor cells. It is not yet known whether radiation therapy and cisplatin are more effective with or without fluorouracil in treating patients with head and neck cancer.
PURPOSE: This randomized phase III trial is studying radiation therapy and cisplatin to compare how well they work with or without fluorouracil in treating patients with stage III or stage IV head and neck cancer.
Condition | Intervention | Phase |
Head and Neck Cancer |
Drug: cisplatin Drug: fluorouracil Procedure: radiation therapy |
Phase III |
MedlinePlus related topics: | Cancer Head and Neck Cancer |
Drug Information available for: | Cisplatin Fluorouracil |
Study Type: | Interventional |
Study Design: | Treatment, Randomized |
Official Title: | A Phase III Randomized Trial Comparing Single Agent Cisplatin With the Combination of 5-Fluorouracil and Cisplatin, Concurrent With Radiation Therapy in Stage III and IV Squamous Cell Head and Neck Cancer |
Estimated Enrollment: | 126 |
Study Start Date: | January 2008 |
Estimated Primary Completion Date: | February 2012 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
Arm I: Active Comparator
Patients undergo full-dose radiotherapy once or twice daily 5 days a week for up to 7 weeks and receive cisplatin IV over 1 hour on days 1, 22, and 43 of radiotherapy.
|
Drug: cisplatin
Given IV
Procedure: radiation therapy
Patients undergo full-dose radiotherapy once or twice daily 5 days a week for up to 7 weeks
|
Arm II: Experimental
Patients undergo radiotherapy as in arm I and receive fluorouracil IV and cisplatin IV continuously on days 1-4 and 22-25 of radiotherapy.
|
Drug: cisplatin
Given IV
Drug: fluorouracil
Given IV
Procedure: radiation therapy
Patients undergo full-dose radiotherapy once or twice daily 5 days a week for up to 7 weeks
|
OBJECTIVES:
OUTLINE: This is a multicenter study. Patients are stratified according to radiotherapy schedule (once daily vs twice daily) and radiotherapy planning (2D vs 3D vs intensity-modulated radiotherapy). Patients are randomized to 1 of 2 treatment arms.
Patients with biopsy-verified residual disease at the primary site or local recurrence after achieving a complete response to chemoradiotherapy may undergo salvage surgery 12 weeks after the completion of chemoradiotherapy.
Patients complete questionnaires periodically to assess late toxicity and quality of life.
After completion of study treatment, patients are followed periodically.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Histologically confirmed squamous cell carcinoma of the oral cavity, oropharynx, larynx, or hypopharynx
Must have locoregionally confined stage III (excluding T1-2, N1) or stage IV disease
Deemed appropriate for definitive non-operative management with curative intent
PATIENT CHARACTERISTICS:
PRIOR CONCURRENT THERAPY:
United States, Ohio | |||||
Case Comprehensive Cancer Center | Recruiting | ||||
Cleveland, Ohio, United States, 44106-5065 | |||||
Contact: Clinical Trials Office - Case Comprehensive Cancer Center 800-641-2422 | |||||
Cleveland Clinic Taussig Cancer Center | Recruiting | ||||
Cleveland, Ohio, United States, 44195 | |||||
Contact: Clinical Trials Office - Cleveland Clinic Taussig Cancer Cente 866-223-8100 | |||||
Geauga Regional Hospital | Recruiting | ||||
Chardonr, Ohio, United States, 44024 | |||||
Contact: Panayiotis Savvides 440-285-6000 | |||||
Lake/University Ireland Cancer Center | Recruiting | ||||
Mentor, Ohio, United States, 44060 | |||||
Contact: Panayiotis Savvides 440-205-5755 | |||||
University Suburban Health Center | Recruiting | ||||
South Euclid, Ohio, United States, 44121 | |||||
Contact: Panayiotis Savvides 216-844-3871 | |||||
Southwest General Health Center | Recruiting | ||||
Middleburgh Heights, Ohio, United States, 44130 | |||||
Contact: Panayiotis Savvides 440-816-8000 | |||||
UHHS Chagrin Highlands Medical Center | Recruiting | ||||
Orange Villager, Ohio, United States, 44122 | |||||
Contact: Panayiotis Savvides 216-292-1783 | |||||
UHHS Westlake Medical Center | Recruiting | ||||
Westlaker, Ohio, United States, 44145 | |||||
Contact: Panayiotis Savvides 440-250-2001 | |||||
Mercy Cancer Center at Mercy Medical Center | Recruiting | ||||
Canton, Ohio, United States, 44708 | |||||
Contact: Panayiotis Savvides 330-430-2788 |
Case Comprehensive Cancer Center |
National Cancer Institute (NCI) |
Principal Investigator: | David J. Adelstein, MD | The Cleveland Clinic |
Clinical trial summary from the National Cancer Institute's PDQ® database 
  |
Responsible Party: | Cleveland Clinic Taussig Cancer Center ( David J. Adelstein ) |
Study ID Numbers: | CDR0000584258, CASE-3307-CC389, CASE-3307, CASE-CC389 |
First Received: | January 30, 2008 |
Last Updated: | October 4, 2008 |
ClinicalTrials.gov Identifier: | NCT00608205 |
Health Authority: | Unspecified |
|
|
|
|
|
|